These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1349492)

  • 1. Dose-dependent alpha 1-adrenoceptor antagonist activity of the anti-arrhythmic drug, abanoquil (UK-52,046), without reduction in blood pressure in man.
    Tham TC; Guy S; Shanks RG; Harron DW
    Br J Clin Pharmacol; 1992 Apr; 33(4):405-9. PubMed ID: 1349492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.
    Schafers RF; Elliott HL; Howie CA; Reid JL
    Br J Clin Pharmacol; 1991 Nov; 32(5):599-604. PubMed ID: 1683249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: II. Duration of action, pharmacokinetics and concentration-effect relationships in normotensive subjects.
    Schafers RF; Elliott HL; Meredith PA; Miller SH; Reid JL
    Br J Clin Pharmacol; 1991 Nov; 32(5):605-10. PubMed ID: 1683250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dose dependency of the alpha-adrenoceptor antagonist and beta-adrenoceptor partial agonist activity of dilevalol and labetalol in man.
    Tham TC; McKaigue JP; Guy S; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1993 Sep; 36(3):251-6. PubMed ID: 9114912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of UK-52,046, an alpha 1-adrenoceptor antagonist, on baroreflex function in man.
    McKaigue JP; Harron DW
    Br J Clin Pharmacol; 1990 Oct; 30(4):579-84. PubMed ID: 1981319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046.
    Spiers JP; Harron DW; Wilson R
    J Pharm Pharmacol; 1991 Jan; 43(1):70-2. PubMed ID: 1676070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.
    Tham TC; Guy S; McDermott BJ; Shanks RG; Riddell JG
    Br J Clin Pharmacol; 1995 Jul; 40(1):19-23. PubMed ID: 8527263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UK-52,046 (a novel alpha 1-adrenoceptor antagonist) and the role of alpha-adrenoceptor stimulation and blockade on atrioventricular conduction.
    Spiers JP; Harron DW; Wilson R; Allen JD
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):824-30. PubMed ID: 1703607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abanoquil, a new alpha-1 adrenoceptor antagonist. In vitro and in vivo effect on erectile tissue.
    Giraldi A; Wyllie M; Wagner G
    Int J Impot Res; 2000 Mar; 12 Suppl 1():S37-40. PubMed ID: 10845763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of acute alpha 1-adrenergic antagonism on heart rate variability in patients with old myocardial infarction.
    Toivonen L
    J Cardiovasc Pharmacol; 1994 Jun; 23(6):932-5. PubMed ID: 7523785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of urapidil on responses to phenylephrine, angiotensin and isoprenaline in man.
    Tomlinson B; Renondin JC; Graham BR; Prichard BN
    Eur J Clin Pharmacol; 1991; 41(1):1-3. PubMed ID: 1685992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of age on the responsiveness of vascular alpha-adrenoceptors in man.
    Elliott HL; Sumner DJ; McLean K; Reid JL
    J Cardiovasc Pharmacol; 1982; 4(3):388-92. PubMed ID: 6177934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian variation of alpha 1-adrenoceptor-mediated pressor response to phenylephrine in man.
    Tham TC; Guy S; Riddell JG; Shanks RG; Harron DW
    J Pharm Pharmacol; 1996 May; 48(5):526-8. PubMed ID: 8799880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function.
    Silke B; Zezulka AV; Verma SP; Tham TC; Taylor SH
    Br J Clin Pharmacol; 1990 Jun; 29(6):749-58. PubMed ID: 1974144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a benzofuroquinolizine alpha 2-adrenoceptor antagonist.
    Gertz BJ; Vlasses PH; Rocci ML; Coker LD; Williams V; Bjornsson TD; Jones KH
    Clin Pharmacol Ther; 1989 Nov; 46(5):566-75. PubMed ID: 2573444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers.
    Karhuvaara S; Kallio A; Scheinin M; Anttila M; Salonen JS; Scheinin H
    Br J Clin Pharmacol; 1990 Jul; 30(1):97-106. PubMed ID: 1975199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of phenylephrine with and without atropine on QT dispersion in healthy normotensive men.
    Yee KM; Lim PO; Ogston SA; Struthers AD
    Am J Cardiol; 2000 Jan; 85(1):69-74. PubMed ID: 11078240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.
    Leto di Priolo S; Priore P; Cocco G; Sfrisi C; Cazor JL
    Eur J Clin Pharmacol; 1988; 35(1):25-30. PubMed ID: 2905990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological basis for antihypertensive effects of intravenous labetalol.
    Richards DA; Prichard BN; Boakes AJ; Tuckman J; Knight EJ
    Br Heart J; 1977 Jan; 39(1):99-106. PubMed ID: 12778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha adrenergic blocking activity of urapidil in man.
    Jamieson MJ; Shepherd AM; Jackson SH; Patel SS; Flanagan PH; Galbraith H
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):173-85. PubMed ID: 2908008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.